SOLICITATION NOTICE
R -- Obtain treatment and mortality data from ERSPC
- Notice Date
- 8/9/2012
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120172-MD
- Archive Date
- 9/7/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics DCEG plans to procure on a sole source basis with Erasmus Medical Center of Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands to obtain treatment and mortality data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541990 and the business size standard is $14 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. In 2009, two important papers published interim results on the efficacy of Protein-Specific Antigen (PSA) Screening for Prostate Cancer from the two largest, cooperative, randomized, controlled trials in the world - one in the United States and the other in Europe. While the European Randomized Study of Screening for Prostate Cancer (ERSPC) indicates a clear benefit of screening, the US based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial showed no benefit. Although the trial results are apparently in conflict, there are many differences in their designs and implementation that makes results comparison difficult. As a consequence, the important question on the benefit of screening prostate cancer with PSA remains unanswered. Modeling provides a unique opportunity to clarify the message on screening benefit contained in the two trials. Understanding the likely benefit of PSA screening on prostate cancer mortality is critical for the general public and the clinical community as a whole. It has high public health significance as well since clinicians and men face the decision of PSA screening for prostate cancer each day. Collecting individual and detailed data from each of the trials is crucial to inform the models and to translate the results of the trials. Resolving the current controversies has the potential to have significant impact in the practice of PSA screening in the United States. The purpose is to obtain treatment and mortality data from the European Randomized Study of Screening for Prostate Cancer (ERSPC), a large and highly-confidential dataset involving a multi-center (7 European countries), to inform the CISNET models and to address the current controversies surrounding the benefits of PSA Screening. Mortality and treatment data are crucial to estimate efficacy of PSA. The European Randomized study of Screening for Prostate Cancer (ERSPC) was established more than 12 years ago and is the largest ever randomized study on screening for prostate cancer. The ERSPC trial is an extremely valuable dataset. What makes this dataset unique is the magnitude of patients enrolled, approximately 182,000 men from 7 European countries, the long follow-up time, high compliance and lower contamination of the control group. The Department of Urology at Erasmus MC is uniquely qualified to perform the work of this contract because they are the holders of the ERSPC data and coordinate and disseminate information for data requests from other European countries. They are also the world leaders in the development of micro-simulation models to investigate the effect of screening strategies on population cancer trends. They are part of the NCI CISNET prostate grant and they have a deep understanding about how data from randomized screening trials can be used to estimate screening efficacy and calibrate models. They are uniquely qualified because they have a deep understanding of modeling as well and the data. Therefore, in the best interest of the government this contract should be awarded to the Department of Urology at Erasmus MC. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 23, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through SAM.gov. No collect calls will be accepted. Please reference solicitation number NCI-120172-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120172-MD/listing.html)
- Record
- SN02833264-W 20120811/120810001128-d6596c726100fae1cc9b76dfbd9c786f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |